A
Abata Therapeutics
Bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis
About Abata Therapeutics
Abata Therapeutics is a pioneering biotech startup focused on developing transformative therapies for autoimmune diseases, with a particular emphasis on type 1 diabetes. The company is leveraging the biology of regulatory T cells (Tregs) to create innovative treatments that aim to significantly improve patient outcomes. Their lead product, ABA 201, is a novel Treg cell therapy designed to benefit patients with type 1 diabetes who still have some remaining beta cell function. Currently, ABA 201 is in the IND (Investigational New Drug) enabling studies phase and is expected to enter clinical trials by 2025.
Read full description
Abata Therapeutics operates in the highly specialized and competitive biotech market, targeting a niche segment of patients suffering from autoimmune diseases. Their primary clients include healthcare providers, research institutions, and ultimately, patients who are in need of advanced therapeutic options for managing autoimmune conditions.
The company’s business model revolves around research and development (R&D) of cutting-edge cell therapies. They generate revenue through strategic partnerships, grants, and future sales of their proprietary treatments. A notable partnership with ElevateBio supports Abata in process development and manufacturing, ensuring that their therapies can be produced at scale and meet regulatory standards.
Abata Therapeutics is driven by a team of industry experts and scientific pioneers committed to pushing the frontiers of science. They value diversity, kindness, and the limitless possibilities that come with innovative research. The company fosters a collaborative and enthusiastic work environment, welcoming new talent to join their mission of transforming the treatment landscape for autoimmune diseases.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Cambridge, United States
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 61.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Abata Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Aug 2024 | $0 | — | Bristol-Myers Squibb | ↗ |
| EARLY VCOther financing | Jun 2022 | $95M | $380M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Abata Therapeutics is 1.3K monthly website visits, down 61.8% over the last three months. Abata Therapeutics's team declined 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Third Rock Ventures
Lightspeed Venture Partners
Invus
JDRF T1D Fund
Samsara BioCapital
Bristol-Myers Squibb
Other known investors2 additional known investors
Harvard University
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Abata Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Abata Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.